This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.
The aim of the study is to see how safe and effective the study drugs are.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
eGFR 30 to 90 mL/min/1.73 m² using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening
Known medical history or clinical evidence indicative of non-diabetic renal disease
Renal disease that required treatment with systemic immunosuppressive therapy, or a history of dialysis or renal transplant
Medically unstable as assessed by the investigator
Hospitalization (ie, >24 hours) within 30 days of the screening visit